Navigation Links
Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research

lopment of rBChE."

Dr. Langermann continued, "These recent data suggest a promising new potential therapeutic application for rBChE, which we intend to explore further. Our next steps, in collaboration with Dr. Soreq and her group, will include evaluating rBChE in animal models of Alzheimer's disease. If the results continue to be encouraging, then it would allow us to expand applications of rBChE therapy to areas other than nerve agent toxicity resulting in broader commercial applications with important benefits to society."

The work conducted under the Alzheimer's research program is based on a patent owned by Yissum (the technology transfer company of The Hebrew University of Jerusalem), entitled "Human BChE Variants as Protectors from Amyloid Diseases", which has been licensed to PharmAthene.

About Protexia(r): Recombinant Human Butyrylcholinesterase (rBChE)

Protexia is a form of recombinant human butyrylcholinesterase (rBChE), a potent organophosphorus (OP) scavenger protein produced in the milk of transgenic goats, which is being developed for use as a prophylactic against acute organophosphorus (OP) nerve agent toxicity.


Preclinical research conducted by PharmAthene's development partners, the US Army Medical Research Institute of Chemical Defence (USAMRICD) and DRDC Suffield, Defence Research and Development Canada, have demonstrated the capability of Protexia to protect laboratory animals from the toxic effects of chemical nerve agents.

In these studies, pre-treatment with rBChE provided 100% survival against the nerve agents VX and soman. In post-exposure therapeutic studies, administration of rBChE following nerve agent exposure resulted in enhanced survival compared to control animals.

While the utility of BChE to protect against nerve agent exposure is well documented, a major limitation in its development has been the inability to produce it in commercial volumes due to limited raw material availa
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimers Research
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
4. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
5. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
6. Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. CuraGen Presents Update on Clinical Development Program for Belinostat
9. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
10. Diatos Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program
11. OXiGENE Abstracts Published in ASCO Program
Post Your Comments:
(Date:9/18/2014)... BURLINGTON, Mass. , Sept. 18, 2014 /PRNewswire/ ... post-launch in the United States ... have prescribed GlaxoSmithKline,s BRAF inhibitor Tafinlar for ... 49 percent who have prescribed GlaxoSmithKline,s MEK inhibitor ... the highest percentage (42 percent and 43 percent, ...
(Date:9/18/2014)... 18, 2014  Iliad Neurosciences, Inc., a company focused ... treating Autism Spectrum Disorders (ASD) announced today that it ... Research Foundation for The State University of New York. ... new biomarker to identify an abnormality in folate transport ... biomarker is expected to be available for research use ...
(Date:9/18/2014)... BURLINGTON, Mass. , Sept. 18, 2014  Decision ... launched anti-vascular endothelial growth factor (VEGF) agent for wet ... and Medicare Advantage plans as Genentech,s Lucentis, which is ... although surveyed managed care organization (MCO) directors do not ... Eylea is slightly more likely than Lucentis to be ...
Breaking Medicine Technology:At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3
(Date:9/18/2014)... (PRWEB) September 18, 2014 Memorial ... made history this week by performing the first ever, ... UNOS (United Network for Organ Sharing) approval to launch ... one of only two programs in South Florida. ... Dr. Enrique Gongora, Medical Director of the ...
(Date:9/18/2014)... -- Older people become more physically vulnerable during bereavement, ... stress hormones during bereavement changes with age, British researchers ... are more likely to have weakened immune systems and ... weeks and months after loss, we can suffer from ... of white blood cell and as such are essential ...
(Date:9/18/2014)... One of the most capable and ... ShandsCair Flight Program’s new EC155 B1, will ... at the Air Medical Transport Conference (AMTC), Sept. 22-24, ... into service ShandsCair EC155 and the Vanderbilt University ... AMTC highlight Airbus Helicopters broad, industry leading line-up of ...
(Date:9/18/2014)... -- Daily supplements of selenium or vitamin E don,t ... cataracts among men, a new study indicates. Previous ... help prevent cataracts. To investigate this further, William Christen, ... in Boston, and his colleagues examined data from a ... trial was initially designed to study prevention of prostate ...
(Date:9/18/2014)... Thousands of college and high school ... fundraising impact on 127 member Children’s Miracle Network ... Dance Marathon Day will officially kick off a school ... raised by college and high school students funding vital ... Dance Marathon campus programs help provide medical equipment, treatment ...
Breaking Medicine News(10 mins):Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4Health News:Grief Can Weigh on Immune System in Older Folks, Study Says 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2
... ... Locally, , ... WA (PRWEB) July 2, 2010 -- Bill the Butcher Inc. opened a neighborhood butcher ... executive officer., , ,Located at 3800 34th Ave West in Seattle,s Magnolia neighborhood, the ...
... patients with Hodgkin lymphoma (HL) and a history of heart ... after completing treatment, according to research published online today in ... Hematology. HL is a form of cancer of arising in ... the disease in 2009, according to the American Cancer Society. ...
... at Karolinska Institutet recommends a new routine for protection ... for feeding directly through the abdominal wall, is surgically ... simpler and cheaper than the one used today. The ... has been clinically tested on over 200 patients at ...
... Register now for ... of women, at the Mariandale Retreat Center -- right outside of NYC, which will be held ... workshops, room and board, is only $350 until July 9, 2010. , ... New York, NY (PRWEB) July 2, 2010 -- Need to get ...
... ... is pleased to announce the Grand Opening of their newly expanded pain treatment center in ... ... are located at 638 West Duarte Road, Suite 18, Arcadia, California 91007. The Los Angeles ...
... ... , ... 1, 2010-- Aromatherapy isn’t new to the field of natural health. Ancient Egyptians were the ... the Romans to modern day, essential oils have been part of a holistic approach to ...
Cached Medicine News:Health News:In Time for July 4th Grilling, Bill the Butcher Opens 5th Butcher Shop 2Health News:Lymphoma patients with cardiovascular disease have increased risk of cardiac hospitalization 2Health News:Simpler and cheaper antibiotic prophylaxis with insertion of nutrition catheter in the stomach 2Health News:Relax, Release and Rejuvenate at Upcoming Women's Retreat 2Health News:Relax, Release and Rejuvenate at Upcoming Women's Retreat 3Health News:Advanced Pain Institute Opens Expanded Los Angeles Area Pain Management Center 2Health News:Certified Organic Aromatherapy Oils Available from Swanson Health Products 2
... An APTT-based kit for the screening of ... specificity of the test for the factor ... sample plasma with an excess of V-DEF ... possible to discriminate between heterozygous and homozygous ...
Inquire...
Inquire...
... remarkable anti-reflux valve is enclosed ... which prevents the valve from ... in sitting or reclining positions. ... and interference free ensuring uninterrupted ...
Medicine Products: